NCT02388594View on ClinicalTrials.gov

A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

September 30, 2018

Study Completion Date

March 31, 2019

Conditions
Human Immunodeficiency Virus (HIV)
Interventions
DRUG

ZFN Modified CD4+ T Cells

DRUG

Cyclophosphamide

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of Pennsylvania

OTHER

NCT02388594 - A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients | Biotech Hunter | Biotech Hunter